BPC-157
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Gastric pentadecapeptide; cytoprotective agent promoting tissue healing via angiogenesis, NO-system modulation, and growth factor upregulation
Quick Facts
| Property | Value |
|---|---|
| Also Known As | Body Protection Compound-157, PL-10, PLD-116, PL 14736, Bepecin |
| Category | Recovery / GI Protection / Neuroprotection |
| Sequence | GEPPPGKPADDAGLV (15 amino acids) |
| Molecular Weight | 1419.56 Da |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| PubChem CID | 108101 |
| Administration | SubQ / Oral / IM / Intravesical / IV |
| Typical Dose Range | 250–500 mcg SubQ 1–2x daily (preclinical extrapolation); up to 20 mg IV in pilot study |
| Half-Life | <30 minutes |
| Storage | Lyophilized: -20°C, stable 1–3 years; Reconstituted: 2–8°C, use within 3–4 weeks |
| FDA Status | Research-only; not FDA-approved; Category 2 bulk drug substance (excluded from compounding) |
| WADA Status | Prohibited under S0 (Non-Approved Substances) |
Mechanism of Action
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its primary mechanism involves the upregulation of VEGFR2 and activation of the PI3K/Akt/eNOS signaling cascade, promoting endothelial cell survival, nitric oxide production, and new blood vessel formation. This angiogenic effect has been consistently observed across multiple tissue types — GI mucosa, tendons, ligaments, skeletal muscle, and cardiac tissue (PMID-29998800, PMID-34267654).
A key distinguishing feature of BPC-157 is its homeostatic modulation of the nitric oxide (NO) system. Rather than simply stimulating or inhibiting NO, BPC-157 normalizes NO levels contextually — counteracting both hypertension and hypotension models. This operates through the Egr-1/NAB2 feedback loop: simultaneous activation of Early Growth Response 1 (repair initiator) and NAB2 (self-limiting brake), which prevents pathological neovascularization while promoting healing-appropriate angiogenesis (PMID-30915550).
BPC-157 also demonstrates significant cytoprotective effects against NSAID-induced toxicity, stabilizing intestinal tight junction proteins and preventing leaky gut syndrome. This gastroprotection extends beyond the GI tract to include hepatoprotection and neuroprotection against NSAID damage (PMID-22950504, PMID-32445447).
Neurologically, BPC-157 modulates both serotonergic and dopaminergic systems, counteracting perturbations in both directions (excess and deficit). It promotes peripheral nerve regeneration and demonstrates neuroprotective effects in stroke, TBI, and spinal cord injury models. This brain-gut axis activity suggests bidirectional signaling, with peripheral administration producing central effects (PMID-27138887, PMID-34380875).
Key Research Areas
-
Musculoskeletal Healing — A 2025 systematic review of 36 studies (35 preclinical, 1 clinical) confirmed consistent enhancement of muscle, tendon, ligament, and bone healing via growth factor upregulation and angiogenesis (PMID-40756949). Staresinic et al. demonstrated accelerated healing of completely transected quadriceps muscle over 72 days with improved biomechanical function and reduced fibrosis (PMID-16609979).
-
GI Mucosal Protection & Cytoprotection — BPC-157 rescues NSAID-induced cytotoxicity by stabilizing intestinal permeability and enhancing tight junction protein expression (PMID-32445447). It counteracts GI, hepatic, and encephalopathic toxicity from multiple NSAIDs including diclofenac and celecoxib (PMID-22950504).
-
Wound Healing — Seiwerth et al. reviewed BPC 157's efficacy across skin wounds, diabetic ulcers, deep burns, fistulas, and various tissue defects. The peptide resolves vessel constriction, stabilizes platelet plugs, and promotes clot dissolution (PMID-34267654).
-
CNS Neuroprotection — Preclinical evidence demonstrates BPC-157 counteracts stroke, TBI, spinal cord injury, and dopaminergic perturbations. The peptide modulates the NO system and dopamine pathways, with peripheral administration producing central effects (PMID-34380875, PMID-27138887).
-
Cardiac and Smooth Muscle — BPC 157 shows therapeutic effects across all three muscle types (striated, smooth, cardiac), restoring injured myotendinous junctions and demonstrating cardioprotective effects in heart failure and arrhythmia models (PMID-36551977).
-
Human Clinical Pilots — Two small human studies have emerged: an IV safety pilot (n=2, up to 20 mg, no adverse effects; PMID-40131143) and an intravesical pilot for interstitial cystitis (n=12, 83% symptom resolution; PMID-39325560). A Phase 2 RCT for hamstring repair (NCT07437547, n=120) is currently recruiting.
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Systematic reviews | 1 | Orthopaedic sports medicine (36 studies synthesized) |
| Human clinical (pilot/case series) | 2 | IV safety (n=2) and interstitial cystitis (n=12); both uncontrolled |
| Animal in vivo | 2 | Quadriceps transection, tendon healing |
| Narrative reviews | 12 | GI protection, wound healing, CNS, muscle, brain-gut axis, safety |
| Total vault studies | 17 |
The evidence base for BPC-157 is extensive preclinically but preliminary clinically. The 2025 systematic review (PMID-40756949) found 35 preclinical studies but only 1 clinical study. Two human pilots (2024-2025) provide the first clinical data but are small and uncontrolled. A proper Phase 2 RCT (NCT07437547) is recruiting. Methodological concern: >70% of published BPC-157 research originates from the Sikiric/Seiwerth group at the University of Zagreb. Independent validation by Józwiak et al. (2025) broadly confirms the field's findings (PMID-40005999).
Clinical Applications
- Tendon and Ligament Repair — Promotes tendon outgrowth, cell survival, and migration; accelerates healing in preclinical models
- Muscle Tears — Enhances recovery of transected and crushed muscle via angiogenesis and reduced fibrosis
- Injury Recovery — Broad musculoskeletal healing across multiple tissue types
- Gut Health — Stabilizes intestinal permeability, protects GI mucosa, counteracts NSAID damage
- Gastric Ulcers — Cytoprotective against NSAID-induced gastric and intestinal ulceration
- Wound Healing — Effective across skin wounds, burns, diabetic ulcers, and fistulas
- Neuroprotection — Preclinical neuroprotection in stroke, TBI, and spinal cord injury models
- Stroke Recovery — Modulates dopamine and NO systems in stroke models
- Post-Procedure Recovery — Accelerates surgical wound and anastomosis healing
- Autoimmune Conditions — Anti-inflammatory effects via NO modulation (preclinical)
- Cancer Adjunct Therapy — Theoretical concern: angiogenesis promotion (contraindication flagged)
Protocols Using This Peptide
- Wolverine Stack Protocol — Core peptide (paired with TB-500 and MGF for tissue repair)
- Recovery Stack Protocol — Core peptide for musculoskeletal recovery
- Gut Healing Protocol — Core peptide for GI mucosal protection and permeability
- Post-Stroke Recovery Protocol — Adjunct for neuroprotection (preclinical basis only)
Ageless Peps Products
- AP-BPC157-Vial — BPC-157 Vial, 5mg/10mg lyophilized, $44 retail / $33 wholesale
- AP-BPC157-500MCG-Capsules — BPC-157 Capsules, 500mcg x 60 caps, $124 retail / $115 wholesale
- AP-BPC157-TB500-Blend — BPC-157/TB-500 Blend Vial, from $65 retail / $60 wholesale
- AP-WOLVERINE-Blend — WOLVERINE Blend (BPC-157 10mg + TB-500 2.5mg + MGF 1mg), $109 retail / $89 wholesale
- AP-GLOW-Blend — GLOW Blend (GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg), from $134 retail / $99 wholesale
- AP-KLOW-Blend — KLOW Blend (GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg), $153 retail / $118 wholesale
- AP-BPC157-TB500-Capsules — BPC-157/TB-500 Capsules, 500mcg/500mcg x 60 caps, $284 retail / $219 wholesale
- AP-BPC157-KPV-Capsules — BPC-157/KPV Capsules, 500mcg/500mcg x 60 caps, $284 retail / $210 wholesale
- AP-Sample-Pack — Sample Pack (GLP-3 + BPC-157 + TB-500), $165 retail / $99 wholesale
Dosing Reference
Research Dosing Ranges
| Route | Dose Range | Frequency | Duration | Source | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SubQ / IM | 250–500 mcg | 1–2x daily | 4–6 weeks | Practitioner guides; extrapolated from animal studies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral | 250–500 mcg | 1x daily | 4–8 weeks | Gastric stability data; PMID-40131143)
Cancer ConsiderationsCONTRAINDICATED in active malignancy. BPC-157 promotes angiogenesis via VEGFR2/Akt/eNOS pathway, which could theoretically support tumor vasculature. No direct cancer studies exist for BPC-157, but the pro-angiogenic mechanism is a well-established concern. Patients with active cancer, history of cancer within 5 years, or cancer predisposition syndromes should NOT use BPC-157 without oncologist clearance. See Compliance/Cancer Safety Matrix for full ratings. Synergistic Combinations
Related Research
References
Related#peptide #recovery #cognitive #subq #oral #iv |